Parliamentary questions can be asked by any MSP to the Scottish Government or the Scottish Parliamentary Corporate Body. The questions provide a means for MSPs to get factual and statistical information.
Urgent Questions aren't included in the Question and Answers search. There is a SPICe fact sheet listing Urgent and emergency questions.
Displaying 43551 questions Show Answers
To ask the Scottish Government what flood defence projects have been approved, and what the value is of each project.
To ask the Scottish Government whether Siemens Gamesa has been contracted to provide any services to it or any bodies for which it is responsible.
To ask the Scottish Government what plans it has to request that the UK Government, its Under2 Coalition partners and other international actors address the issue of loss and damage, which was debated at COP26.
To ask the Scottish Government what funding is available to free advice and law centres, and for how long this funding will be available.
To ask the Scottish Government what (a) financial and (b) other support (i) it, (ii) enterprise agencies and (iii) its other bodies and agencies have offered to Siemens Gamesa.
To ask the Scottish Government how many pharmacy closures there have been in each of the last 12 months, and what information it has on the reason for each closure.
To ask the Scottish Government what measures it is putting in place to monitor the (a) safety, (b) efficacy and (c) quality of cannabis-based products for medicinal use, following reports of cannabidiol (CBD) being of inconsistent quality and having poor safety labelling.
To ask the Scottish Government what impact the introduction of vaccine passports has had on COVID-19 transmission numbers.
To ask the Scottish Government, further to the answer to question S6W-03377 by Humza Yousaf on 18 October 2021, (a) how many and (b) which elective surgeries have (i) been cancelled and (ii) taken place in NHS Greater Glasgow and Clyde in each month since January 2021.
To ask the Scottish Government, in light of guidance published by the Joint Committee on Vaccination and Immunisation on 1 September 2021, advising that patients with severe immunosuppression should receive a third dose of the COVID-19 vaccine, whether people with Monoclonal Gammopathy of Undetermined Significance will be included in the clinically high-risk cohort and therefore eligible to receive a third primary dose.